Time filter

Source Type

Napoli, Italy

Balducci L.,H. Lee Moffitt Cancer Center and Research Institute | Cova D.,Primario Emerito Onco Geriatra | Repetto L.,UOC Oncologia
Geriatric and Medical Intelligence | Year: 2010

In the elderly cancer patient, it seems to be very important to make a global clinical assessment and a multidimensional and multispecialistic evaluation. Advanced age alone is not a sufficient reason to exclude an effective treatment which could improve quality of life as well as survival of these patients, however the presence of specific age-related conditions such as concomitant diseases, geriatric syndromes, poor nutritional status, and poor socio-economic conditions can increase the risk of complications due to antineoplastic treatment. Specific studies in the elderly must be performed in order to establish strategies for treating elderly patients on a scientific basis. Several parameters have to be taken into account before defining the subiect's age, as chronological age or biological age. Ageing is associated with multi-dimensional changes, such as alterations of physiological functions, comorbidities and poly-medications. This may result in modifications of the absorption, distribution, metabolism and excretion of the drugs. In literature there are few studies reporting the pharmacokynetics and pharmacodynamics in elderly patients suffering from cancer. These aspects are here discussed by the Authors, especially proposing the optimal dosing for individual elderly patients in order to achieve targeted drug exposure. © Dario Cova. Source

Wildiers H.,University Hospitals Leuven | Brain E.,Institute Curie Hopital Rene Huguenin Saint Cloud | Penninckx B.,EORTC Headquarters | Ring A.,Sussex Cancer Center | And 5 more authors.
European Journal of Cancer, Supplement | Year: 2012

The EORTC Cancer in the ElderlyTask Force (ETF) aims to develop, conduct, coordinate and stimulate research on elderly patients with cancer. Towards this goal, the ETF has established close interactions with disease-oriented EORTC groups by having representatives from most of these groups attend the ETF meetings. In addition, the ETF reviews every new protocol for elderly-specific questions within the protocol review process of the EORTC aiming to reduce ageism within study protocols. Since 2006, the ETF decided to focus on three aspects: open a discussion on specific methodology for clinical trials in the older population; create a common language for describing heterogeneity between older individuals, the EORTC minimal dataset for geriatric assessment in older cancer patients; and develop specific clinical trials in the older population. This article reports the achievements of the ETF in these three domains and discusses its future strategies. © 2012 European Organisation for Research and Treatment of Cancer. Source

Procopio G.,Science Oncologia Medica 1 | Derosa L.,Oncologia Medica 2 Universitaria | Gernone A.,Oncologia Medica Universitaria | Morelli F.,UOC Oncologia | And 19 more authors.
Future Oncology | Year: 2014

Aim: The Italian Retrospective Analysis of Sorafenib as First or Second Target Therapy study assessed the efficacy and safety of sorafenib in metastatic renal cell carcinoma patients treated in the community. Patients & methods: Patients receiving first- or second-line single-agent sorafenib between January 2008 and December 2010 were eligible. Retrospective data collection started in 2012 and covers at least 1-year follow-up. The primary end point was overall survival (OS). Results: Median OS was 17.2 months (95% CI: 15.5-19.6): 19.9 months (95% CI: 15.9-25.3) in patients treated with first-line sorafenib and 16.3 months (95% CI: 13.1-18.2) with second-line sorafenib. Overall median (95% CI) progression-free survival was 5.9 months (95% CI: 4.9-6.7): 6.6 (95% CI: 4.9-9.3) and 5.3 months (95% CI: 4.3-6.0) in first- and second-line patients, respectively. Conclusion: The efficacy and safety of sorafenib in routine community practice was generally good, especially in relation to OS in patients treated in the second line, where results were similar to those seen in recent prospective clinical trials. © 2014 Future Medicine Ltd. Source

Di Lorenzo G.,University of Naples Federico II | Buonerba C.,University of Naples Federico II | Faiella A.,University of Naples Federico II | Rescigno P.,University of Naples Federico II | And 14 more authors.
BJU International | Year: 2011

OBJECTIVE To determine the activity and tolerability of docetaxel re-treatment after first-line therapy with docetaxel in castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS Between November 2005 and January 2009, 45 patients initially responding to docetaxel and then experiencing disease progression after a period of biochemical remission of at least 5 months were enrolled in a prospective multicenter study and re-treated with docetaxel. The primary endpoint was the biochemical response (biochemical partial response defined as >50% prostate-specific antigen [PSA] decline); secondary endpoints were objective response, toxicity, progression-free survival (PFS) and overall survival (OS). RESULTS Partial PSA responses were observed in 11 patients (24.5%), 4 (25%) of whom also had an objective response. The treatment was well tolerated, with grade 1-2 neutropenia, thrombocytopenia, vomiting and peripheral neuropathy noted in 18 (40%), 11 (24.5%), 8 (17.8%), and 6 (13.3%) patients, respectively. The most common grade 3 toxicity was neutropenia, which was observed in 8 patients (17.8%). Median PFS was 5 months and median OS was 13 months. CONCLUSIONS Docetaxel re-treatment preserves anti-tumour activity and is well tolerated in a selected population of pretreated patients with CRPC. Further randomized trials are needed to confirm our preliminary results. © 2010 BJU INTERNATIONAL. Source

Riccardi F.,UOC Oncologia | Nappi O.,UOC Anatomia Patologica | Balzano A.,UOC Gastroenterologia | De Palma M.,UOC Endocrinochirurgia | And 17 more authors.
International Journal of Immunopathology and Pharmacology | Year: 2011

Neuroendocrine tumors (NETs) are rare, with an incidence of about 5 per 100,000 inhabitants. As no study on NETs has ever been specifically conducted on the population of Campania, we performed a retrospective analysis of all newly diagnosed NETs at the "Antonio Cardarelli" hospital between 2006-2009. A search of the registry of the Pathology Department of the "Antonio Cardarelli" hospital was carried out to retrieve available data on all newly diagnosed NET cases. Two hundred and ninety-nine NET tumors were diagnosed at our Institution from January, 2006 to December, 2009. Globally, 121 patients (40% of the population) had a lung NET, while 92 patients (30% of the population) presented a GEP-NET. The most common primary tumor site varied by sex, with female patients being more likely to have a primary NET in the lung, breast or colon, and male patients being more likely to have a primary tumor in the lung. Also, twenty-three cases of breast NETs were identified, and clinical information regarding therapy and response was available for 22 patients. Our study represents a pioneering effort to provide the medical community in Campania with basic information on a large number of patients with different types of NETs. The "Antonio Cardarelli" hospital could greatly benefit from cooperation with other hospitals in order to become a highly specialized center for NETs in the region and Southern Italy. Copyright © by BIOLIFE, s.a.s. Source

Discover hidden collaborations